|Mr. Robert J. Hugin MBA||Exec. Chairman||9.1M||N/A||62|
|Mr. Mark J. Alles||Pres, Chief Operating Officer and Director||4.33M||10.42M||58|
|Mr. Scott Andrew Smith||Pres and Chief Operating Officer||1.52M||N/A||55|
|Mr. Peter N. Kellogg BSE, MBA||Chief Financial Officer, Chief Accounting Officer and Exec. VP||2.23M||N/A||61|
|Dr. Jacqualyn A. Fouse Ph.D.||Strategic Advisor and Director||4.54M||N/A||56|
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The companys products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc.; The company was founded in 1980 and is headquartered in Summit, New Jersey.
Celgene Corporation’s ISS Governance QualityScore as of April 1, 2017 is 1. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 2; Compensation: 1.